Abstract
The purpose of the study was to evaluate the effectiveness of fenofibrate and sildenafil at various dosages in the treatment of Alzheimer’s disease. Sildenafil is an up-regulator of brain-derived neurotrophic factor (BDNF), whereas fenofibrate is a powerful PPAR-α activator. The typical medication was rivastigmine, while the inducer was AlCl3 . The tests of spatial working memory included the MWM, Y-Maze, and NOR. Moreover, the levels of Aβ, PPAR-α, BDNF, TNF-α, and IL-1β in the brain were measured using ELISA kits. During the probing session, the MWM displayed a decline in escape latency and rise in the target quadrant entry. The results of the Y-maze and the NOR demonstrated the emergence of spontaneous changes in the discrimination and recognition index scores. The therapy groups showed decline in the levels of TNF-α, IL-1β, and Aβ. The brain histology of the treated group showed moderate neurodegeneration. From this study, we can conclude that fenofibrate and sildenafil when used in combination could be a successful treatment for AD.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call